加拿大现实世界研究 长期临床结果 使用dupilumab治疗长期鼻炎与息肉
1Department of Otolaryngology-Head and Neck Surgery, University of Ottawa, The Ottawa Hospital, Ottawa, ON, Canada.
概括
治疗慢性鼻多性鼻炎 (CRSwNP) 的dupilumab治疗显著改善了长达三年的生活质量. 现实数据显示,在受杜皮卢马布治疗的CRSwNP患者中,症状持续减少.
科学领域:
- 免疫学 免疫学 免疫学
- 耳鼻喉科 耳鼻喉科 耳鼻喉科
- 药理学 药理学是指药理学的学科.
背景情况:
- 杜皮卢马布是一种抗IL4受体α抗体,是加拿大首个批准用于CRSwNP.NP的生物药物.
- 临床试验表明dupilumab可以减少多体大小,症状严重程度,并改善生活质量,具有可接受的安全性.
- 这项研究提供了长期的现实数据,介绍了CRSwNP患者的鼻治疗结果,这些患者接受多皮卢马布治疗长达三年.
研究的目的:
- 评估dupilumab在治疗带鼻多的慢性鼻炎 (CRSwNP) 中的长期,现实世界的有效性.
- 评估CRSwNP患者在治疗开始后长达三年的疾病特异性鼻结局和生活质量的持续改善.
主要方法:
- 来自加拿大鼻科中心的电子医疗记录的回顾性审查.
- 包括接受dupilumab并完成至少一个后续检查的CRSwNP患者.
- 利用中鼻结局测试 (SNOT-22) 来测量症状的改善.
主要成果:
- 99名患者开始使用dupilumab治疗.
- 平均SNOT-22得分从基线时的61.1显著下降到一年后的16.75,两年后的15.02,三年后的10.22.
- 这项研究观察到,在三年治疗期间,鼻治疗结果和生活质量持续改善.
结论:
- 现实数据证实,dupilumab在CRSwNP患者的疾病特异性生活质量中保持了长达三年的显著改善.
- 杜皮卢马布在治理CRSwNP症状和改善临床环境中的患者结果方面表现出持续的有效性.
- 长期的杜皮卢马布治疗与患有鼻多的慢性鼻炎的患者的持续益处有关.
相关概念视频
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
01:26COPD: Management Using Bronchodilators and Corticosteroids
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...